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Research has shown differences in subcortical brain volumes between participants with 
schizophrenia and healthy controls. However, none of these differences have been found to 
associate with schizophrenia polygenic risk. Here, in a large sample (n= 14,701) of 
unaffected participants from the UK Biobank, we test whether schizophrenia polygenic risk 
scores (PRS) limited to specific gene-sets predict subcortical brain volumes. We compare 
associations with schizophrenia PRS at the whole genome level (‘genomic’, including all 
SNPs associated with the disorder at a P-value threshold < 0.05) with ‘genic’ PRS (based on 
SNPs in the vicinity of known genes), ‘intergenic’ PRS (based on the remaining SNPs), and 
genic PRS limited to SNPs within 7 gene-sets previously found to be enriched for genetic 
association with schizophrenia (‘abnormal behaviour,’ ‘abnormal long-term potentiation,’ 
‘abnormal nervous system electrophysiology,’ ‘FMRP targets,’ ‘5HT2C channels,’ ‘CaV2 
channels’ and ‘loss-of-function intolerant genes’). We observe a negative association 
between the ‘abnormal behaviour’ gene-set PRS and volume of the right thalamus that 
survived correction for multiple testing (ß= -0.031, pFDR= .005) and was robust to different 
schizophrenia PRS P-value thresholds. In contrast, the only association with genomic PRS 
surviving correction for multiple testing was for right pallidum, which was observed using a 
schizophrenia PRS P-value threshold < 0.01 (ß= -0.032, p= .0003, pFDR= .02), but not when 
using other PRS P-value thresholds. We conclude that schizophrenia PRS limited to 
functional gene sets may provide a better means of capturing differences in subcortical brain 






Schizophrenia (SZ) is a highly heritable (h2 ~ 80%)1 psychiatric disorder that can carry a 
severe burden for affected individuals and their families. Recent advances in our 
understanding of the genetic risk for SZ have confirmed its polygenic nature, with hundreds – 
if not thousands2 - of common risk alleles explaining ~25% of the variance in liability to the 
disorder3. The most recent published Genome Wide Association Study (GWAS) identified 
145 independent loci associated with SZ at genome-wide significance4. Despite the increase 
in our understanding of the genetic factors related to SZ, our knowledge about its 
neurobiological underpinnings remains scarce. Although recent large multicentric studies 
have consistently shown differences in subcortical brain volumes between SZ participants 
and healthy controls5,6, research looking at the combined risk effect of common alleles using 
polygenic risk scores (PRS)7 has shown no association between PRS for SZ and subcortical 
volumes8-10. This could suggest that these differences in subcortical volumes are a 
consequence, as opposed to a premorbid risk marker, of schizophrenia; albeit other 
interpretations are also plausible, for example that these are driven by environmental risk. 
However, previous research has also shown similar subcortical abnormalities in unaffected 
relatives of SZ patients11-14 and in healthy carriers of rare alleles penetrant for SZ15, 
suggesting that at least some of these subcortical differences could well represent 
intermediate phenotypes for SZ that lie on the causal pathway between genetic variation and 
expression of the disorder. Identifying brain intermediate phenotypes is key for our 
understanding of the mechanisms behind SZ, unveiling its etiopathogenesis and ultimately 
developing more effective clinical interventions. 
 
An alternative explanation for the lack of association could be the potential heterogeneity in 
the effect of risk alleles across the brain. It is possible that only a subset of SZ associated 
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variants would relate to the size of subcortical structures16, and even then not all subcortical 
volumes would necessarily associate to the same subset of variants. So far, research in this 
area has applied PRS optimised to account for the presence of SZ in the population, but this 
should not necessarily be optimal to account for brain variability. PRS based on biologically 
driven gene-sets may outperform the genome-wide PRS in explaining brain phenotypes. 
Examples of that are recent studies attempting to identify ‘core gene-sets’ that make a larger 
contribution to SZ risk17, or to predict brain anatomy18 and functional connectivity19 via PRS 
limited to genes up- or down-regulated by MIR13720. 
 
In this proof-of-concept exploratory study we aim to revisit the association between common 
allele risk for SZ and subcortical brain volumes using different strategies to calculate PRS in 
a large sample of unaffected participants from the UK Biobank cohort. We compare the 
associations of the genome-wide PRS for SZ (henceforth genomic PRS) with subcortical 
brain volumes, to those associations where PRS is limited to loci within genes (genic PRS) or 
loci outside those genomic regions (intergenic PRS). We also calculate PRS based on seven 
gene sets that previous research has shown to be particularly enriched for common and rare 
SZ risk variants4,21. These will serve the purpose of testing our hypothesis that reducing 
heterogeneity within the SNPs included in PRS improves its ability to predict subcortical 
volume variability, guiding future research in this area towards identifying gene-sets that 
maximize brain phenotype variance explained, rather than simply adding new significant 
SNPs from future GWASs through an ‘omic’ PRS approach. However, we are assuming here 
that these gene sets have the ability to influence brain structure, and it should also be noted 
that other gene-sets based on different criteria – eg. gene ontology terms – could have been 
equally selected. We are also hypothesising that different gene-set PRS will show association 
with particular subcortical volumes, showing heterogeneity of effects across them, rather than 
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suggesting a common mechanism of action. We expect PRS to show the same direction of 
effect shown in clinical research: negative associations between the volume of most 




This study used a subsample of participants from the UK Biobank (www.ukbiobank.ac.uk), a 
UK population cohort of ~500,000 participants recruited between 2006-2010 when aged 40–
69 years, and followed-up since. Our initial sample included those participants from whom 
brain MRI anatomical images (T1) were available at the time of the analyses (n= 20,664). All 
subjects provided informed consent to participate in UK Biobank. Ethical approval was 
granted by the North West Multi-Centre Ethics committee. Data were released to Cardiff 
University after application project reference 17044. 
 
Only participants self-reporting White British or Irish descent for whom European ancestry 
was subsequently confirmed through genetic analysis22 were included in the study. Related 
participants up to second degree relatives (kinship coefficient > 0.15) were excluded by 
randomly removing one participant from the related pair. Furthermore, in order to avoid 
reverse causation effects, participants were excluded if a personal history for severe 
psychiatric disorders (i.e. SZ, psychosis, bipolar disorder, autistic spectrum disorder or 
intellectual disability) or medical/neurological conditions that could affect brain anatomy (i.e. 
alcohol dependence, dementia, Parkinson’s, neurodegenerative disorders or brain cancer) 




After applying the above inclusion/exclusion criteria and the genetic QC below, the final 
sample included 14,701 participants, with a mean age of 62 years (sd: 7.4, range: 45-80) and 
51% female. 
 
Genotyping and PRS computation 
Genotyping was performed by UK Biobank using the Affymetrix UK BiLEVE Axiom array 
(807,411 probes) on an initial 50,000 participants, and the Affymetrix UK Biobank Axiom® 
array (820,967 probes) for the remaining participants. The two arrays are extremely similar 
(with over 95% common content). Sample processing at UK Biobank has been previously 
described23 and resulted in the release of the 488,377 samples that went into our PRS 
calculations. 
  
In order to calculate PRS, a random subset of 5,000 UK biobank participants not included 
here and matched by age and gender distribution with our sample were used as an LD 
reference dataset for pruning and clumping of SNPs (7,232,075 total). We retained SNPs in 
our sample with a minor allele frequency ³5% and a Hardy-Weinberg equilibrium p-value 
³10-6. Correlated SNPs were pruned using r2=0.2, a physical distance threshold of 1Mb, 
preferentially retaining the SNP most significantly associated with SZ4. SNPs within the 
extended MHC locus (chr6:25Mb-35Mb) were excluded due to high levels of linkage 
disequilibrium in the region, as were insertion/deletion polymorphisms and ambiguous flip 
SNPs. Genetic principal components 1 – 10 were included as population stratification 
covariates in the calculation of the scores. We initially used a p-threshold of 0.05 since this 
has shown to maximally capture polygenic risk across a large number of independent 
samples24. For comparison, analyses spanning a range of p-thresholds (0.5, 0.1, 0.01, 0.001, 
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0.0001) were also conducted. All scores were calculated in PLINK v1.90b5.4 64-bit via 
Stata/IC 13.1 (https://github.com/ricanney/stata) using best-guess genotypes.  
 
For genomic PRS, full summary statistics from the latest available GWAS4 were used 
(7,248,434 SNPs). For genic PRS, the summary file was trimmed to contain only SNPs that 
were located within 35Kb upstream and 10Kb downstream of genes detailed in the 
comprehensive GENCODE 31 human gene list (https://www.gencodegenes.org). 
Pseudogenes were removed, leaving a total of 19,965 genes, which produced a summary file 
containing 5,363,146 SNPs. The intergenic PRS was calculated from the SNPs that were not 
retained in the genic PRS summary file (1,885,288 SNPs). Seven gene-set PRS were 
generated following the exact same steps than used for the genic PRS, but in this case SNPs 
included in each PRS were limited to those contained in genes within that gene set. Three of 
these sets derive from the Mouse Genome Informatics database25 and relate to behavioural 
and neurophysiological correlates of learning: abnormal behaviour (MP:0004924; 717,522 
SNPs spanning over 2,037 genes included in the PRS), abnormal long term potentiation 
(MP:0002207; 68,686 SNPs from 157 genes included in the PRS), abnormal nervous system 
electrophysiology (MP:0002272; 106,641 SNPs included in 213 genes considered in the 
PRS). The other four sets included: targets of the fragile X mental retardation protein 26 
(FMRP targets; 403,723 SNPs from 839 genes included in the PRS), the 5-HT2C receptor 
complex27 (5HT2C channels; 4,435 SNPs included in 18 genes considered in the PRS), the 
voltage-gated calcium channel complexes28 (CaV2 channels;107,987 SNPs from 207 genes 
included in the PRS) and loss of function intolerant genes as defined by the Exome 
Aggregation Consortium29 using their gene-level constraint metric (pLI ³ 0.9) (LoF 




Brain images were acquired using Siemens Skyra 3T scanners in UK Biobank’s imaging 
centres in Cheadle (n=7,683), Reading (n= 5,599) and Newcastle (n= 1,419) using identical 
acquisition protocols (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=2367). T1-weighted 
NIfTI brain images were processed in our lab using FreeSurfer v5.3 
(https://surfer.nmr.mgh.harvard.edu) to automatically obtain estimates of subcortical volumes 
(i.e. thalamus, caudate, putamen, pallidum, nucleus accumbens, hippocampus and amygdala). 
To avoid values potentially resulting from deficient segmentation of tissue types, extreme 
values defined as ±3 standard deviations from the group mean were removed from each 
corresponding analysis (0.3% - 0.8% of the total sample). Bilateral subcortical volumes were 
obtained by averaging the volume of left and right subcortical structures. 
 
Analyses 
Regression analyses were run with each bilateral brain volume as the outcome variable and 
PRS as predictor, after accounting for the effect of intracranial volume, sex, age and 
acquisition centre, using IBM SPSS Statistics v25. Although we accounted for population 
stratification when calculating PRS, the first 5 genetic principal components were also 
included as covariates in the regression models to control for any potential residual effects. 
Significance threshold was set at p<0.05 (two-sided), and False Discovery Rate (FDR; 0.1) 
based on Benjamini-Hochberg30 was used to correct for multiple testing. Due to the 
exploratory nature of this study, we report uncorrected (nominal) p values throughout, along 
with the corrected p value (pFDR) for those associations that survive multiple testing 
correction. We first tested the association between genomic PRS and the volume of each 
seven subcortical structures; followed by the same analyses for genic PRS and intergenic 
PRS. Finally, we tested the association of each gene-set PRS against each subcortical volume. 
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In order to examine potential interhemispheric differences, further analyses were run for each 
hemisphere. Finally, to explore the optimal PRS p-threshold to inform future research and to 
examine the stability of results as an index of validity, we expanded our analyses to PRS 
calculated under a wider range of p-thresholds (i.e. 0.5, 0.1, 0.01, 0.001, 0.0001). We 
compared the performance of different PRS based on the statistical significance of the 
associations found, their effect size (i.e. beta value) and their stability across different p-
thresholds. Therefore, we considered the best PRS predictive of subcortical volumes to be 
those that produced FDR-corrected significant associations with the highest beta value, 
reproduceable at different p-thresholds. 
 
Results 
PRS (p-threshold <0.05) associations with left-right averaged subcortical volumes 
No association was found between genomic PRS and subcortical volumes. Likewise, genic 
PRS did not show association with any subcortical volumes. Intergenic PRS, though, showed 
negative nominal significant associations with the size of the putamen and the amygdala, 
although neither of these were significant after FDR correction (Table 1). 
 
Three gene set PRS – abnormal behaviour, FMRP targets and LoF intolerant – showed 
negative associations with the volume of the thalamus, although only the former remained 
significant after FDR correction (b=-0.030, p=.00005, pFDR= .002, adjusted R2= 0.50, R2 
change= 0.001). FMRP targets gene-set PRS was also associated positively with the volume 
of the pallidum and negatively with the hippocampus, although only at nominal level (Table 
1). 
   ---------- insert Table 1 ----------- 
Within-hemisphere analyses 
 10 
Genomic PRS showed negative nominal associations with left caudate and putamen, and right 
pallidum; none of these significant after FDR correction. The same nominal associations 
were found for the genic PRS; whereas, again, intergenic PRS appeared more strongly 
associated – negative - with the volume of the amygdala in the right hemisphere (Table 2). 
 
Gene set PRS analyses showed similar results than above, although the negative association 
between abnormal behaviour PRS and thalamic volume was now only FDR-corrected 
significant for the right hemisphere (b=-0.031, p=.00005, pFDR= .005, adjusted R2= 0.46, R2 
change= 0.001; Table 2). 
   ------------- Insert Table 2 -------------- 
Alternative p-thresholds 
Genomic PRS showed negative nominal associations with the volume of the right pallidum at 
several p-thresholds, this surviving FDR-correction at p-threshold <0.01 (ß= -0.032, p= 
.0003, pFDR= .02, adjusted R2= 0.27, R2 change= 0.0003; Figure 1). A similar pattern of 
associations was found for genic PRS, again with the strongest association shown at p-
threshold 0.01 with the right pallidum, although in this case it did not survive FDR 
correction. Intergenic PRS showed overall a similar pattern of associations to genomic and 
genic PRS, but in relation to the right amygdala. In this case, intergenic PRS showed a 
negative nominal association across most p-thresholds that was not present in genic PRS, 
with the largest effect size shown at p-threshold 0.1 (b= -0.027, p= 0.002, pFDR= .14, adjusted 
R2= 0.32, R2 change= 0.001; Figure 2). 
   -------------- Insert Figures 1, 2 ------------- 
We further investigated the association between abnormal behaviour PRS and subcortical 
volumes. We found negative FDR-corrected significant association between this PRS at all p-
thresholds and the volume of the right thalamus, the strongest at p-threshold <0.05 as 
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reported above (Figure 3). Abnormal behaviour PRS, though, did not show any other stable 
association across p-thresholds with subcortical volumes, at either nominal or FDR-corrected 
significant level. For completeness, the results from the same analyses for all gene-sets 
considered previously are presented in the supplemental figure 1. None of these showed 
FDR-corrected significant associations with subcortical volumes, and only abnormal nervous 
system electrophysiology PRS and FMRP targets PRS showed stable negative nominal 
associations across several p-thresholds with the left caudate and the left thalamus 
respectively. 
   -------------- Insert Figure 3 ------------- 
Discussion 
In this proof-of-concept study we revisited the association between polygenic risk for SZ and 
subcortical volumes using the largest and therefore most powered GWAS published to date4 
in a uniquely large sample of unaffected participants, also examining the effect of restricting 
common allele risk to gene sets known to be enriched for SZ4,21. Our results showed that 
schizophrenia polygenic risk restricted to certain gene sets predicted more variance of 
neuroimaging biomarkers than an overall genomic approach. Moreover, we found 
considerable heterogeneity on the effects over subcortical volumes of different gene sets. 
 
As previously reported using earlier GWAS training data8-10, we did not find any significant 
associations between genomic PRS for SZ and bilateral subcortical volumes. Dividing this 
into its genic and intergenic components did not dramatically change that picture, both these 
scores showing no significant associations with any subcortical volume, with the exception of 
nominal negative associations between intergenic PRS and putamen and amygdala volumes. 
Accounting for hemisphere changed these results only slightly, with nominal associations 
with left putamen and right pallidum now appearing, but none surviving FDR correction. Of 
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notice, though, the hemispheric divide clearly strengthened the association between the 
intergenic PRS and amygdala volume, confined to the right hemisphere, despite still falling 
short of the FDR-corrected threshold. Interestingly, though, genic PRS showed not even a 
trend to associate with the volume of the amygdala. This result suggests that long-range gene 
regulatory variation lying outside our genic windows account for most of the volume 
variability within the right amygdala. If replicated, the importance of intergenic effects will 
bring the challenge of further dissecting core elements within it. 
 
The analyses of gene-set PRS brought a different picture of the association between common 
allele risk for SZ and subcortical anatomy. The abnormal behaviour PRS showed a negative 
FDR-corrected significant association with the volume of the thalamus. Considering 
hemisphere, this association was present at FDR-corrected level for right thalamus, whereas 
only at nominal level for the left thalamus. The LoF intolerant PRS and the FMRP targets 
PRS also showed a negative nominal association with the size of the thalamus, with the latter 
also being associated with hippocampal (negative) and pallidum (positive) volumes. The 
strategy of limiting our PRS calculations to gene-sets, as opposed to a genomic or genic 
approach, proved to be more successful in capturing subcortical anatomical variation. 
 
Since the selection of the SNP p-threshold initially used (i.e. p< 0.05) was based on its ability 
to best capture the global polygenic common variant risk burden for SZ, but not necessarily 
variants associated with brain anatomy, we repeated our analyses using a wide range of p-
thresholds above and below the initial 0.05. Overall, results showed that p<0.05 was not the 
optimal threshold in most instances. For example, the previous nominal association between 
genomic PRS and the volume of the right pallidum, reached FDR-corrected significance level 
with a PRS calculated at a p-threshold <0.01. Similarly, the association between intergenic 
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PRS and the volume of the pallidum and amygdala would have been FDR-significant if 
initially calculated at p-threshold <0.01; however, since at this stage we were performing a 
larger number of tests, these fell short of the FDR threshold. In relation to the association 
between genomic PRS and volume of the pallidum, the latter has shown to be increased in 
participants with SZ compared to healthy participants5,6; however, we find that the higher the 
common allele risk for SZ, the smaller the volume of the pallidum. Previous research from 
our group has shown the same negative association in a much smaller sample of healthy 
participants using an earlier GWAS as the training dataset31, and also comparing healthy 
participants carrying rare variants penetrant for SZ against participants not carrying any 
damaging rare allele15. Together, these findings suggest that previous clinical research 
showing larger pallidum in people with SZ could have been concealed by confounders linked 
to clinical status – e.g. use of antipsychotic drugs32, suggesting that this would not be a trait 
marker of risk, but a state marker of the presence of the disorder. 
 
Abnormal behaviour PRS showed FDR-corrected significant associations with the right 
thalamus volume for all p-thresholds applied, proving the stability and robustness of this 
association. Interestingly, the analyses using genomic and genic PRS did not detect any 
association with thalamic size, suggesting that only a restricted number of variants included 
in genes within this gene-set may determine the development of the thalamus to its adult size. 
The inclusion of many other variants in ‘omic’ approaches with potentially no-effect – or 
effects in the opposite direction - will dilute this association making it invisible to commonly 
used approaches. It is worth noting as well that this gene-set PRS did not show any clear 
pattern of association with any other subcortical volume, suggesting a rather specific effect of 
genes included in it, at least with regard to subcortical anatomy. The abnormal behaviour 
gene set consists of genes identified as modifying behaviour via single-gene manipulation 
 14 
studies in mouse. The range of behavioural tests, and by implication the range of neural 
circuits, covered by this set is extremely broad, which complicates any mechanistic 
interpretation of the associations found in our study. It seems likely that considerably larger 
imaging cohorts will be required to identify more specific functional associations within this 
set of genes that could be interpretable from a biologically mechanistic approach. The PRS 
restricted to the FMRP targets gene-set also showed a stable association with the volume of 
the left thalamus across several p-thresholds; however, these only reached nominal 
significance and would require further replication in more powered samples before any 
conclusions can be extracted. All these associations between common allele risk and thalamic 
volume followed the predicted direction based on previous clinical research5,6; that is, a 
negative association indicating that the higher the risk for the disorder, the lower the volume 
of the thalamus, making it a target for research into SZ risk biomarkers. 
Other interesting results from our gene-set analysis are: a) The positive nominal significant 
association between FMRP targets PRS and pallidum volume, opposing the negative 
association of this volume with genomic PRS discussed above. It could be argued that only 
variants within FMRP target genes influence the pallidum’s development in the direction of 
risk for SZ, most other variants potentially influencing in the opposite direction. However, 
due to this association not surviving FDR correction, this interpretation remains rather 
speculative and would require replication in more powered samples before any conclusions 
can be drawn. 2) Despite the required caution interpreting negative results, it is surprising 
that LoF intolerant PRS did not show any robust association with subcortical volumes, when 
considering that this gene set explains the largest amount of SNP heritability and shows the 
strongest association with SZ compared to other gene sets. However, it is important to note 
that gene sets that appear scarcely associated with subcortical volumes could exert their 
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influence on SZ via other relevant biomarkers (e.g. cortical anatomy or white matter content) 
not explored here. 
 
There are caveats to our work that require mentioning: 1) Although, to our knowledge, this is 
the largest dataset of healthy participants ever interrogated for association between common 
allele risk and subcortical volumes, statistical power is still limited when considering the 
small effect sizes obtained. Future releases of UK Biobank data and other large 
imaging/genetic resources should allow for replication studies and meta-analyses. 2) We 
based our PRS on the latest/largest GWAS published to date4, but the future release of the 
results from the Psychiatric Genomics Consortium’s latest GWAS should allow for a more 
accurate and powered calculation of PRS. Also, whilst our study did not include patients, 
there is still a small chance that a few of the healthy participants from UKBB were included 
as controls in Pardiñas et al GWAS4; future studies should therefore try to de-duplicate these 
samples. 3) We selected gene sets based on previous work from our group showing 
enrichment for SZ variants4,21; however, this is not necessarily an optimal criterion when 
testing gene-set PRS association with brain phenotypes. In this respect, future work should 
develop methods to test optimal aggregation of variants that can best predict these – and other 
– phenotypes. 4) Finally, it is important to note that due to the recruitment strategy, the UK 
Biobank cohort is not a truly representative sample of the general population but a cohort of 
participants on average healthier and demographically more educated and wealthier33. 
 
In summary, we present here the results of a proof-of-concept study in which we challenge 
the use of an ‘omic’ PRS approach to examine the effects of SZ allele risk on brain 
phenotypes. The alternative strategy of limiting PRS calculations to smaller gene-sets based 
on an a-priori biologically informed criterion proved more successful in capturing subcortical 
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volume variance than the genomic or genic approach, supporting the idea that common allele 
risk for SZ impact subcortical brain anatomy and suggesting thalamic volume as an important 
target in future research into risk markers for SZ. The observed level of heterogeneity across 
gene-set PRS effects on subcortical volumes could partly explain the lack of success in 
previously published genome-wide PRS approaches. Future research should focus on the 
optimisation of gene-sets that could better account for interindividual brain variability, 
potentially inputting information on gene expression at key developmental stages and its 
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Table 1. Association (Beta) between polygenic scores (genomic, genic, intergenic & gene-sets) and subcortical volumes averaged across 
hemispheres 
 
   Thalamus  Caudate Putamen  Pallidum Accumbens Hippocampus Amygdala 
PRS Pt=0.05       b     (p)      b      (p)     b     (p)      b      (p)     b      (p)      b      (p)      b     (p) 
Genomic -0.006 (.41) -0.015 (.10) -0.012 (.19) -0.013 (.17) -0.006 (.51) -0.007 (.45) -0.008 (.34) 
Genic -0.008 (.26) -0.013 (.13) -0.012 (.19) -0.010 (.29) -0.007 (.47) -0.007 (.44) -0.006 (.49) 
Intergenic -0.001 (.87) -0.014 (.15) -0.018 (.05) -0.016 (.09) -0.011 (.25) -0.008 (.37) -0.021 (.02) 
5HT2C   0.004 (.63) -0.003 (.75) -0.005 (.57) -0.006 (.54) -0.007 (.46) -0.002 (.82)  0.007 (.43) 
abnormal_beh -0.030 (.00005)* -0.014 (.10) -0.004 (.68)  0.003 (.75) -0.003 (.73) -0.013 (.12) -0.001 (.87) 
abnormal_ltp -0.007 (.32) -0.016 (.07) -0.007 (.42)  0.01 (.29) -0.002 (.83) -0.001 (.88)  0.005 (.55) 
abnormal_nse  0.010 (.19) -0.014 (.10) -0.012 (.18) -0.003 (.75) -0.004 (.69)  0.006 (.50)  0.001 (.95) 
CaV2 channels  0.002 (.78) -0.001 (.90) -0.000 (.97)  0.008 (.41) -0.009 (.35)  0.004 (.64)  0.003 (.75) 
FMRP targets -0.019 (.01) -0.010 (.27)  0.011 (.21)  0.019 (.04) -0.004 (.66) -0.021 (.01) -0.002 (.82) 
LoF intolerant -0.016 (.03)  0.002 (.82) -0.002 (.84)  0.002 (.82)  0.011 (.26) -0.011 (.19) -0.002 (.85) 
P values reported in this table are uncorrected. Nominally significant associations are highlighted in italic. Significant associations after FDR 
correction (7 tests for genomic PRS, 14 for genic/intergenic PRS, 49 for gene-set PRS) are highlighted with an asterisk. 5HT2C: 5-HT2C receptor 
complex genes set; abnormal_beh: abnormal behaviour genes set; abnormal_ltp: abnormal long term potentiation genes set; abnormal_nse: 
abnormal nervous system electrophysiology; CaV2 channels: voltage-gated calcium channel complexes genes set; FMRP targets: targets of 





Table 2. Association between polygenic scores (genomic, genic, intergenic & gene-sets) and subcortical volumes for left and right hemispheres 
separately. 
 
 Thalamus Caudate Putamen Pallidum Accumbens Hippocampus Amygdala 
PRS Pt=0.05       b     (p) b   (p) b   (p) b   (p) b   (p) b   (p) b   (p) 
Left hemisphere       
Genomic -0.005 (.52) -0.017 (.05) -0.019 (.04) -0.008 (.43) -0.009 (.37) -0.014 (.12) -0.008 (.39) 
Genic -0.004 (.65) -0.018 (.05) -0.020 (.03) -0.006 (.53) -0.009 (.34) -0.010 (.26) -0.005 (.60) 
Intergenic -0.004 (.64) -0.014 (.12) -0.019 (.04) -0.011 (.28) -0.014 (.16) -0.010 (.28) -0.012 (.18) 
5HT2C   0.010 (.23) -0.000 (.96) -0.007 (.44) -0.004 (.65) -0.011 (.23) -0.002 (.86)  0.001 (.91) 
abnormal_beh -0.020 (.01) -0.013 (.15) -0.010 (.26)  0.002 (.81) -0.010 (.27) -0.011 (.19) -0.012 (.16) 
abnormal_ltp -0.008 (.33) -0.013 (.14) -0.008 (.36)  0.006 (.55)  0.003 (.73)  0.004 (.68) -0.002 (.82) 
abnormal_nse -0.004 (.58) -0.017 (.06) -0.013 (.15) -0.003 (.74) -0.001 (.88)  0.004 (.61) -0.011 (.22) 
CaV2 channels  0.005 (.54) -0.005 (.61) -0.002 (.82)  0.005 (.63) -0.003 (.75) -0.003 (.73) -0.000 (.98) 
FMRP targets -0.017 (.03)  0.004 (.63)  0.005 (.59)  0.017 (.09) -0.005 (.57) -0.015 (.08) -0.004 (.64) 
LoF intolerant -0.010 (.21) -0.001 (.90) -0.008 (.38) -0.000 (.97)  0.011 (.24) -0.007 (.39) -0.003 (.76) 
Right hemisphere       
Genomic -0.008 (.30) -0.013 (.14) -0.002 (.86) -0.022 (.02) -0.009 (.35) -0.010 (.25) -0.013 (.12) 
Genic -0.009 (.21) -0.014 (.11) -0.003 (.70) -0.018 (.04) -0.003 (.74) -0.006 (.48) -0.005 (.60) 
Intergenic -0.001 (.88) -0.013 (.16) -0.010 (.25) -0.015 (.09) -0.015 (.12) -0.010 (.27) -0.023 (.009) 
5HT2C   0.006 (.41) -0.002 (.80) -0.004 (.65) -0.000 (.98) -0.008 (.41) -0.002 (.82)  0.010 (.24) 
abnormal_beh -0.031 (.00005)* -0.008 (.34)  0.004 (.65) -0.000 (.96)  0.004 (.70) -0.014 (.11)  0.010 (.26) 
abnormal_ltp -0.009 (.26) -0.018 (.04) -0.018 (.04)  0.001 (.93) -0.003 (.73) -0.002 (.80)  0.011 (.22) 
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abnormal_nse -0.010 (.19) -0.008 (.35) -0.005 (.59)  0.002 (.84) -0.005 (.56)  0.003 (.75)  0.017 (.05) 
CaV2 channels -0.004 (.56)  0.004 (.68)  0.009 (.32)  0.009 (.32) -0.009 (.35) -0.001 (.95) -0.000 (.96) 
FMRP targets -0.015 (.06)  0.009 (.29)  0.004 (.64)  0.008 (.38) -0.001 (.89) -0.016 (.06) -0.005 (.56) 
LoF intolerant -0.010 (.19)  0.009 (.29)  0.006 (.50) -0.006 (.53)  0.015 (.12) -0.011 (.21)  0.001 (.91) 
P values reported in this table are uncorrected. Nominally significant associations are highlighted in italic. Significant associations after FDR 
correction (14 tests for genomic PRS, 28 for genic/intergenic PRS, 98 for gene-set PRS) are highlighted with an asterisk. 5HT2C: 5-HT2C 
receptor complex genes set; abnormal_beh: abnormal behaviour genes set; abnormal_ltp: abnormal long term potentiation genes set; 
abnormal_nse: abnormal nervous system electrophysiology; CaV2 channels: voltage-gated calcium channel complexes genes set; FMRP targets: 





Figure 1. Genomic PRS - calculated at different p thresholds - association with left and right 
subcortical volumes. The direction and length of the bar correspond to the Beta value, the 
associated uncorrected p value is added for each Beta/bar. For comparison, this figure also 
includes the results for the p-threshold <0.05 used in previous analyses. FDR correction 
based on 70 tests (FDR significant results are mark with an asterisk). 
 
Figure 2. Genic (top two) and intergenic (bottom two) PRS – at different p thresholds – 
association with left and right subcortical volumes. The direction and length of the bar 
correspond to the Beta value, the associated uncorrected p value is added for each Beta/bar. 
For comparison, this figure also includes the results for the p-threshold <0.05 used in 
previous analyses. FDR correction based on 70 tests. 
 
Figure 3. Abnormal behaviour gene set PRS calculated a different p thresholds association 
with left and right subcortical volumes. The direction and length of the bar correspond to the 
Beta value, the associated uncorrected p value is added for each Beta/bar. For comparison, 
this figure also includes the results for the p-threshold <0.05 used in previous analyses. FDR 
correction based on 70 tests (FDR significant results are mark with an asterisk)
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